Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials.

ABSTRACT:

Background

Neoadjuvant treatment has proven beneficial for many gastrointestinal (GI) malignancies, but no phase III trials have been completed examining this approach in pancreatic cancer. This meta-analysis examines the best available phase II trials using neoadjuvant treatment for resectable and borderline/unresectable pancreatic adenocarcinoma.

Methods

Phase II trials were identified using a MEDLINE search, and the Cochrane Central Register of Controlled Trials from 1960 to July 2010. Patients were divided into 2 groups: Patients with initially resectable tumors (group A), and patients with borderline/unresectable tumors (group B). Primary outcome measures were rate of resection and survival. Pooled proportions and 95% confidence intervals (CIs) were calculated using ran

SUBMITTER: Assifi MM 

PROVIDER: S-EPMC3164966 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature